Free Trial
NASDAQ:CNTX

Context Therapeutics Q3 2023 Earnings Report

Context Therapeutics logo
$0.86 -0.01 (-0.99%)
As of 12:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Context Therapeutics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.30
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Context Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Context Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Context Therapeutics' Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Context Therapeutics Earnings Headlines

What is William Blair's Forecast for CNTX Q1 Earnings?
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Context Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Context Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Context Therapeutics and other key companies, straight to your email.

About Context Therapeutics

Context Therapeutics (NASDAQ:CNTX), a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

View Context Therapeutics Profile

More Earnings Resources from MarketBeat